Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexiletine in pediatric myotonic disorders
NCT04624750Phase 3Completed
- Sponsor
- Lupin Limited
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fresolimumab in myotonic dystrophy (DM) and non-dystrophic myotonia (NDM), sponsored by Lupin Limited. Primary endpoints: Number and frequency of adverse events and serious adverse events, Incidence of adverse events of special interest and 2 more. Started Sep 2021; status: completed.
02
Drugs
fresolimumab
03
Conditions
myotonic dystrophy (DM)non-dystrophic myotonia (NDM)
Beyond the preview
Go deeper on NCT04624750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624750.